Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Liabilities and Shareholders Equity (2022 - 2025)

Coya Therapeutics (COYA) has disclosed Liabilities and Shareholders Equity for 4 consecutive years, with $50.0 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 12.63% to $50.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $153.9 million through Dec 2025, down 2.15% year-over-year, with the annual reading at $50.0 million for FY2025, 12.63% up from the prior year.
  • Liabilities and Shareholders Equity hit $50.0 million in Q4 2025 for Coya Therapeutics, up from $32.0 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $50.0 million in Q4 2025 to a low of $8.4 million in Q4 2022.
  • Historically, Liabilities and Shareholders Equity has averaged $31.1 million across 4 years, with a median of $35.6 million in 2024.
  • Biggest five-year swings in Liabilities and Shareholders Equity: skyrocketed 391.48% in 2023 and later decreased 16.24% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $8.4 million in 2022, then surged by 391.48% to $41.3 million in 2023, then increased by 7.48% to $44.3 million in 2024, then rose by 12.63% to $50.0 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for COYA at $50.0 million in Q4 2025, $32.0 million in Q3 2025, and $33.5 million in Q2 2025.